Open Access

Functional analysis of polymorphisms in the COX‑2 gene and risk of lung cancer

  • Authors:
    • Joyce L. Moraes
    • Amanda B. Moraes
    • Veronica Aran
    • Marcelo R. Alves
    • Luciene Schluckbier
    • Mariana Duarte
    • Edson Toscano
    • Mauro Zamboni
    • Cinthya Sternberg
    • Emanuela de Moraes
    • José R. Lapa E Silva
    • Carlos Gil Ferreira
  • View Affiliations

  • Published online on: February 16, 2017     https://doi.org/10.3892/mco.2017.1167
  • Pages: 494-502
  • Copyright: © Moraes et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

The enzyme cyclooxygenase 2 (COX‑2) is known to be involved in tumorigenesis and metastasis in certain types of cancer. Nevertheless, the prognostic value of COX‑2 overexpression and its polymorphisms in patients with non‑small cell lung cancer (NSCLC) have yet to be fully elucidated. The aim of the present study was to investigate the association between the three most commonly studied COX‑2 gene polymorphisms (‑1195 G/A, ‑765 G/C and 8473 T/C) with COX‑2 expression and lung cancer risk in a Brazilian cohort. In the present hospital based, case‑control retrospective study, 104 patients with NSCLC and 202 cancer free control subjects were genotyped for ‑1195 G/A, ‑765 G/C and 8473 T/C polymorphisms using allelic discrimination with a reverse transcription quantitative polymerase chain reaction method. COX‑2 mRNA expression was analyzed in surgically resected tumors from 34 patients with NSCLC. The results revealed that COX‑2 expression levels were higher in tumor tissue compared with normal lung tissue. However, this overexpression of COX‑2 was not associated with the patient outcome, and furthermore, none of the analyzed polymorphisms were associated with the risk of developing lung cancer, COX‑2 overexpression, or the overall survival of the patients with NSCLC. Taken together, the findings described in the present study do not support a major role for COX‑2 polymorphisms and COX‑2 overexpression in lung carcinogenesis within the Brazilian population.
View Figures
View References

Related Articles

Journal Cover

April 2017
Volume 6 Issue 4

Print ISSN: 2049-9450
Online ISSN:2049-9469

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Moraes, J.L., Moraes, A.B., Aran, V., Alves, M.R., Schluckbier, L., Duarte, M. ... Gil Ferreira, C. (2017). Functional analysis of polymorphisms in the COX‑2 gene and risk of lung cancer. Molecular and Clinical Oncology, 6, 494-502. https://doi.org/10.3892/mco.2017.1167
MLA
Moraes, J. L., Moraes, A. B., Aran, V., Alves, M. R., Schluckbier, L., Duarte, M., Toscano, E., Zamboni, M., Sternberg, C., de Moraes, E., Lapa E Silva, J. R., Gil Ferreira, C."Functional analysis of polymorphisms in the COX‑2 gene and risk of lung cancer". Molecular and Clinical Oncology 6.4 (2017): 494-502.
Chicago
Moraes, J. L., Moraes, A. B., Aran, V., Alves, M. R., Schluckbier, L., Duarte, M., Toscano, E., Zamboni, M., Sternberg, C., de Moraes, E., Lapa E Silva, J. R., Gil Ferreira, C."Functional analysis of polymorphisms in the COX‑2 gene and risk of lung cancer". Molecular and Clinical Oncology 6, no. 4 (2017): 494-502. https://doi.org/10.3892/mco.2017.1167